Drug Trial Radar · NCT03178552
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 22, 2017
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Conditions
- Non-Small Cell Lung Cancer
Interventions
AlectinibDrug
Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
AtezolizumabDrug
Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
PemetrexedDrug
Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
CisplatinDrug
Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
CarboplatinDrug
Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
GemcitabineDrug
Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
EntrectinibDrug
Participants will receive entrectinib 600 mg orally QD.
CobimetinibDrug
Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
VemurafenibDrug
Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
BevacizumabDrug
Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
DivarasibDrug
Participants will receive divarasib PO QD until disease progression or unacceptable toxicity.
DocetaxelDrug
Participants will receive IV docetaxel Q3W (75 mg/m\^2) until disease progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
- Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
- Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on RECIST v1.1 in bTMB PP1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
- Cohort D: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
- Cohort E: Time in Response (TIR) as Assessed by the Investigator Based on RECIST v1.1Time frame: Month 12
- Cohort F: Investigator-Assessed Objective Response Rate (ORR) Based on RECIST v1.1Time frame: Baseline up to disease progression or death (up to approximately 6 years)
- Cohort G: Incidence of Adverse Events (AEs)Time frame: Baseline to last dose of study treatment + 30 days or until initiation of new anticancer therapy, whichever occurs first (up to approximately 6 years)
Locations
161 sites in 27 countries. Site status is shown where the registry gives one.
UC Davis
Sacramento, California
Rocky Mountain Cancer Center
Denver, Colorado
SCRI Florida Cancer Specialists South
Fort Myers, Florida
Florida Cancer Specialist, North Region
St. Petersburg, Florida
University of Kentucky
Lexington, Kentucky
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Weill Cornell Medical College-New York Presbyterian Hospital
New York, New York
Montefiore Medical Center
The Bronx, New York
Oregon HSU
Portland, Oregon
St. Luke's University Health network
Bethlehem, Pennsylvania
Sarah Cannon Research Institute / Tennessee Oncology
Chattanooga, Tennessee
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina
Hospital Italiano
Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Royal North Shore Hospital
St Leonards, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Ashford Cancer Center Research
Kurralta Park, South Australia, Australia
UZ Brussel
Brussels, Belgium
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Instituto Nacional de Cancer - INCa
Rio de Janeiro, Brazil
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
William Osler Health System Brampton Civic Hospital
Brampton, Ontario, Canada
London Health Sciences Centre · Victoria Hospital
London, Ontario, Canada
Lakeridge Health Center
Oshawa, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
IUCPQ (Hôpital Laval)
Québec, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Bradford Hill Centro de Investigaciones Clinicas
Recoleta, Chile
Beijing Cancer Hospital
Beijing, China
Hunan Cancer Hospital
Changsha, China
The second Xiangya hospital of central south university
Changsha, China
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.